DURACLON how supplied storage and handling: Difference between revisions

Jump to navigation Jump to search
No edit summary
 
Line 6: Line 6:


==Indications and Usage==
==Indications and Usage==
NDC 67457-218-10, 100 mcg/mL solution in
10 mL vials, packaged individually.


<ref name="dailymed.nlm.nih.gov">{{Cite web  | last =  | first =  | title = DURACLON (CLONIDINE HYDROCHLORIDE) INJECTION, SOLUTION [MYLAN INSTITUTIONAL LLC] | url = http://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=8c126bb8-732a-4949-8754-2f50b5543638#i4i_clinical_pharmacology_id_a61d4026-7aae-4211-9bb5-332675db4e46 | publisher =  | date =  | accessdate = 6 February 2014 }}</ref>
NDC 67457-219-10, 500 mcg/mL solution in
10 mL vials, packaged individually.
 
Store at 20° to 25°C (68° to 77°F). [See USP Controlled Room Temperature.]
 
Preservative Free. Discard unused portion.
 
Duraclon® is a licensed registered trademark.
 
Manufactured for:
Mylan Institutional LLC
Rockford, IL 61103 U.S.A.
 
Manufactured by:
Mylan Institutional
Galway, Ireland


0764L102
REVISED JUNE 2012
MI:DURAIJ:R2


To request medical information or to report suspected adverse reactions, contact Drug Safety at 1-877-446-3679 (1-877-4-INFO-RX) or FDA at 1-800-FDA-1088 or www.fda.gov/medwatch
<ref name="dailymed.nlm.nih.gov">{{Cite web  | last =  | first =  | title = DURACLON (CLONIDINE HYDROCHLORIDE) INJECTION, SOLUTION [MYLAN INSTITUTIONAL LLC] | url = http://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=8c126bb8-732a-4949-8754-2f50b5543638#i4i_clinical_pharmacology_id_a61d4026-7aae-4211-9bb5-332675db4e46 | publisher =  | date =  | accessdate = 6 February 2014 }}</ref>


==References==
==References==

Latest revision as of 17:41, 6 February 2014

Clonidine
CATAPRES® FDA Package Insert
Indications and Usage
Dosage and Administration
Dosage Forms and Strengths
Contraindications
Warnings and Precautions
Adverse Reactions
Drug Interactions
Use in Specific Populations
Overdosage
Description
Clinical Pharmacology
Nonclinical Toxicology
Clinical Studies
How Supplied/Storage and Handling
Patient Counseling Information
Labels and Packages
CLONIDINE patch ® FDA Package Insert
Indications and Usage
Dosage and Administration
Dosage Forms and Strengths
Contraindications
Warnings and Precautions
Adverse Reactions
Drug Interactions
Use in Specific Populations
Overdosage
Description
Clinical Pharmacology
Nonclinical Toxicology
Clinical Studies
How Supplied/Storage and Handling
Patient Counseling Information
Labels and Packages
DURACLON (clonidine hydrochloride) injection® FDA Package Insert
Indications and Usage
Dosage and Administration
Dosage Forms and Strengths
Contraindications
Warnings and Precautions
Adverse Reactions
Drug Interactions
Use in Specific Populations
Overdosage
Description
Clinical Pharmacology
Nonclinical Toxicology
Clinical Studies
How Supplied/Storage and Handling
Patient Counseling Information
Labels and Packages
Clinical Trials on Clonidine
ClinicalTrials.gov

Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]; Associate Editor(s)-in-Chief: Pratik Bahekar, MBBS [2]

For patient information, click here.

Indications and Usage

NDC 67457-218-10, 100 mcg/mL solution in 10 mL vials, packaged individually.

NDC 67457-219-10, 500 mcg/mL solution in 10 mL vials, packaged individually.

Store at 20° to 25°C (68° to 77°F). [See USP Controlled Room Temperature.]

Preservative Free. Discard unused portion.

Duraclon® is a licensed registered trademark.

Manufactured for: Mylan Institutional LLC Rockford, IL 61103 U.S.A.

Manufactured by: Mylan Institutional Galway, Ireland

0764L102 REVISED JUNE 2012 MI:DURAIJ:R2

To request medical information or to report suspected adverse reactions, contact Drug Safety at 1-877-446-3679 (1-877-4-INFO-RX) or FDA at 1-800-FDA-1088 or www.fda.gov/medwatch [1]

References

  1. "DURACLON (CLONIDINE HYDROCHLORIDE) INJECTION, SOLUTION [MYLAN INSTITUTIONAL LLC]". Retrieved 6 February 2014.

Template:Antimigraine preparations